Navigation Links
Jazz Pharmaceuticals to Report Third Quarter 2013 Financial Results on November 5, 2013
Date:10/22/2013

DUBLIN, Oct. 22, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to provide a business and financial update and discuss third quarter 2013 financial results.

Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.  A replay of the webcast will be archived on the website for one week.

Audio webcast/conference call:
U.S. Dial-In Number:  +1 800 591 6942
International Dial-In Number: +1 617 614 4909
Passcode: 48257479

A replay of the conference call will be available through November 12, 2013 and accessible through one of the following telephone numbers and entering the passcode:

Replay U.S. Dial-In Number: +1 888 286 8010
Replay International Dial-In Number:  +1 617 801 6888
Passcode: 18933289

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs.  The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.  The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD and FazaClo LD.  Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division.  For further information, see www.jazzpharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 Under the impetus ... packaging market size increased year by year at ... to 2021, the market size will maintain the ... to outnumber RMB140 billion in 2021, thanks to ... development of biological agents and supporting policies. ...
(Date:3/22/2017)... March 22, 2017 New Jersey,s ... of patient harm and saved $641 million in healthcare ... in a national quality improvement program. ... for Patients-New Jersey, part of a national initiative from ... selected the New Jersey Hospital Association and its affiliate, ...
(Date:3/22/2017)... Mar 22, 2017 Research and Markets ... Point Inhibitors Market & Clinical Pipeline Insight 2022" drug ... ... & Clinical Pipeline Insight 2022 report gives comprehensive insight on ... of immune check point inhibitors as main streamline drugs in ...
Breaking Medicine Technology:
(Date:3/22/2017)... Jacksonville, FL (PRWEB) , ... March 22, 2017 ... ... (ASPC) convened experts to create a PCSK9 inhibitor prior authorization (PA) form for ... high cholesterol. It is one of the helpful tools published as part of ...
(Date:3/22/2017)... ... 22, 2017 , ... Wash Tower Ltd. has released a series of six ... the world's first standalone constant pressure bidet. , The videos in the series titled ... https://www.washtower.com as well as on its social media pages. , Each video stars ...
(Date:3/22/2017)... ... 22, 2017 , ... University Orthopedics (UOI) today announced the ... Hand, Upper Extremity and Microvascular Surgery at Newport Hospital. Dr. Bragdon specializes in ... and Hand Surgery. , As the leader of comprehensive orthopedic care in ...
(Date:3/22/2017)... ... March 22, 2017 , ... SNL Insurance and Financial, a ... business owners in the greater Hampton Roads area, is embarking on a community ... Life event. , Each year, hundreds of people living in the South Hampton ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... planning assistance, and related services to families and business owners in the greater ... with the Leukemia & Lymphoma Society. , Every 3 minutes, someone in America ...
Breaking Medicine News(10 mins):